Publications of CTRG


1. H L Kong, M J Boyer, R Lim, S Clarke, M J Millward, J E Wong: Phase II trial of Thalidomide in unresectable hepatocellular carcinoma (HCC). Proceedings of American Society of Clinical Oncology (ASCO), Vol 20, #2282, 2001.

2. AYC Chang, W Yeo, JM Beith, JEL Wong; JHS, CUHK, SCC, NUS. Phase I/II study of weekly paclitaxel, UFT and leucovorin in patients with metastatic breast cancer. Proceedings of American Society of Clinical Oncology (ASCO), Vol 21, #1962, 2002.

3. RA Soo, HL Lim, LZ Wang, SC Lee, LT Tok, HS Lee, BC Goh. Phase I/II study of gemcitabine administered at a constant rate infusion in combination with carboplatin in chemo-naive patients with non-small cell lung cancer. Proceedings of American Society of Clinical Oncology (ASCO), Vol 21, #2754, 2002.

4. JM Beith, BC Goh, W Yeo, A Sullivan, S Lim, S Zhong, LP Rivory: Inter-ethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. Proceedings of American Society of Clinical Oncology (ASCO), Vol 21, #252, 2002.

5. M. J. Millward, M. J. Boyer, M. Lehnert, S. Clarke, D. Rischin, B.-C. Goh, J. Wong, E. McNeil, and J. F. Bishop. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003 14: 449-454.

6. T. W.-T. Leung, F. Mo, C. K. Leow, H. L. Kong, M. J. Boyer, P. Kho, A. Chang, B. Lai, A. T. C. Chan, J. Wong, for the Cancer Therapeutics Research Group. Multicenter validation of the Chinese University Prognostic Index (CUPI) for hepatocellular carcinoma (HCC). Proceedings of American Society of Clinical Oncology (ASCO), Vol 22, #1040, 2003.

7. A. T. C. Chan, M. M. Hsu, B. C. Goh, E. P. Hui, T. W. Liu, M. Millward, A. Y. Chang, B. B. Ma, R. L. Hong, X. Lin, for the Cancer Therapeutics Research Group; MERCK Pte Ltd. Singapore. A phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy. Proceedings of American Society of Clinical Oncology (ASCO), Vol 22, #2000, 2003.

8. Soo RA, Lim HL, Wang LZ, Lee HS, Millward MJ, Tok LT, Lee SC, Lehnert M, Goh BC. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study. Cancer Chemother Pharmacol 2003 Aug; 52(2):153-8.

9. Anthony T.C. Chan, Mow-Ming Hsu, Boon C. Goh, Edwin P. Hui, Tsang-Wu Liu, Michael J. Millward, Ruey-Long Hong, Jacqueline Whang-Peng, Brigette B.Y. Ma, Ka F. To, Matthias Mueser, Nadia Amellal, Xiao Lin, Alex Y. Chang. Multicenter, Phase II Study of Cetuximab in Combination with Carboplatin in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma. Journal of Clinical Oncology Apr 4 2005: 200502147.

10. Wing M Ho, B Ma, Tony Mok, W Yeo, Paul Lai, R Lim, Jane Koh, YY Wong, Ann King, CK Leow, ATC Chan. Liver Resection after Irinotecan, 5-Fluorouracil, and Folinic acid for Patients with Unresectable Colorectal Liver Metastases. A Multicenter Phase II Study by the Cancer Therapeutics Research Group. Medical Oncology, vol 22, no. 1, 2005.

11. A Multicenter Randomized Phase II Study of Carboplatin in Combination with Gemcitabine at Standard Rate or Fixed Dose Rate Infusion in Patients with Advanced Stage Non-Small-Cell Lung Cancer. Annals of Oncology July 2006; 17(7):1128-33.

12. Multi-centre phase II trial of thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol 2006; 46(2):234-8.

13. Phase II Study of Irofulven in recurrent or metastatic gastric cancer: a cancer Therapeutics Research Group (CTRG) study. Proceedings of American Society of Clinical Oncology (ASCO) 2006.

14. Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). The pharmacogenomics journal Feb 2007 / 59: 295-300.

15. Multicentre phase II trial of thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta oncologica 2007; 46:234-238.

16. High incidence of symptomatic methemoglobinemia (metHb) in Asian patients (pts) treated with 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, triapine) and gemcitabine (GEM) in a second-line phase II trial of metastatic non-small cell lung. American Society of Clinical Oncology (ASCO) abstract 1820; 2007.

17. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, TriapineÒ) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Investigational New Drugs Apr 2008; 26(2):169-173.

18. Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012;30(27):3361-7.

 


Features